Pfizer Inc. and Merck & Co. Inc. have announced they will test Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a multi-center, open label, Phase 1b clinical study ... Read more